![Renato T. Skerlj](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Renato T. Skerlj
Chief Executive Officer at Expansion Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Scott Rocklage | M | 69 |
Expansion Therapeutics, Inc.
![]() Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | - |
Matthew D. Disney | M | - |
Expansion Therapeutics, Inc.
![]() Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | - |
Gary Bridger | M | 61 |
Expansion Therapeutics, Inc.
![]() Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 2 years |
Beth Seidenberg | M | 67 |
Expansion Therapeutics, Inc.
![]() Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 6 years |
Andrew Phillips | M | 53 |
Expansion Therapeutics, Inc.
![]() Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | - |
Laura Tadvalkar | F | - |
Expansion Therapeutics, Inc.
![]() Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 3 years |
Raymond Kelleher | M | 59 |
Expansion Therapeutics, Inc.
![]() Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Jeffrey Abrams | M | 68 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 10 years |
Bill Adams | M | 62 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 9 years |
Ken Galbraith | M | 61 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | - |
Geoffrey W. Henson | M | 76 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 7 years |
Eve Elizabeth Slater | M | 78 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | - |
Francis David Duke Scott | M | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 10 years |
Gary Calandra | M | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | - |
Elisabeth Whiting | F | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 5 years |
Mark Levonyak | M | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 1 years |
Paul Brennan | M | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 4 years |
Kamran Alam | M | 50 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 3 years |
Diane Gardiner | F | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 12 | 63.16% |
United States | 7 | 36.84% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Renato T. Skerlj
- Personal Network